Posted by Michael Wonder on 16 Apr 2022
When will SMA oral drug Evrysdi get insurance benefits?
14 April 2022 - Roche’s new spinal muscular atrophy oral treatment Evrysdi (risdiplam) proved the benefit of convenience and cost reduction for patients through new data.
However, the discussion over reimbursement for Evrysdi has dragged on for over one year and a half since the drug’s arrival in Korea, frustrating Korean spinal muscular atrophy patients.
